Alarming inflammation: The TGFβ1–Nrp1 pathway upregulates the IL‐33 axis in lung ILC2s

AllergyVolume 77, Issue 11 p. 3471-3472 NEWS & VIEWS Alarming inflammation: The TGFβ1–Nrp1 pathway upregulates the IL-33 axis in lung ILC2s Lorenzo Salvati, Corresponding Author Lorenzo Salvati [email protected] orcid.org/0000-0001-5831-0392 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Correspondence Lorenzo Salvati and Alessio Mazzoni, Department of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. Email: [email protected]; [email protected]Search for more papers by this authorAlessio Mazzoni, Corresponding Author Alessio Mazzoni [email protected] orcid.org/0000-0001-7768-3805 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Correspondence Lorenzo Salvati and Alessio Mazzoni, Department of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. Email: [email protected]; [email protected]Search for more papers by this author Lorenzo Salvati, Corresponding Author Lorenzo Salvati [email protected] orcid.org/0000-0001-5831-0392 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Correspondence Lorenzo Salvati and Alessio Mazzoni, Department of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. Email: [email protected]; [email protected]Search for more papers by this authorAlessio Mazzoni, Corresponding Author Alessio Mazzoni [email protected] orcid.org/0000-0001-7768-3805 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Correspondence Lorenzo Salvati and Alessio Mazzoni, Department of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. Email: [email protected]; [email protected]Search for more papers by this author First published: 12 August 2022 https://doi.org/10.1111/all.15478Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. CONFLICT OF INTEREST The authors declare that they have no potential conflict of interest. REFERENCES 1Maggi L, Mazzoni A, Capone M, Liotta F, Annunziato F, Cosmi L. The dual function of ILC2: From host protection to pathogenic players in type 2 asthma. Mol Aspects Med. 2021; 80:100981. doi:10.1016/j.mam.2021.100981 2Zhang J, Qiu J, Zhou W, et al. Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity. Nat Immunol. 2022; 23(2): 237-250. doi:10.1038/s41590-021-01097-8 3Bottoms SE, Howell JE, Reinhardt AK, Evans IC, McAnulty RJ. Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma. PLoS One. 2010; 5(3):e9674. doi:10.1371/journal.pone.0009674 4Shikhagaie MM, Björklund ÅK, Mjösberg J, et al. Neuropilin-1 is expressed on lymphoid tissue residing LTi-like group 3 innate lymphoid cells and associated with ectopic lymphoid aggregates. Cell Rep. 2017; 18(7): 1761-1773. doi:10.1016/j.celrep.2017.01.063 5Salvati L, Maggi L, Annunziato F, Cosmi L. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma. Curr Opin Allergy Clin Immunol. 2021; 21(6): 590-596. doi:10.1097/ACI.0000000000000793 6Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021; 385(18): 1656-1668. doi:10.1056/NEJMoa2024257 7Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021; 148(3): 790-798. doi:10.1016/j.jaci.2021.03.044 Volume77, Issue11November 2022Pages 3471-3472 ReferencesRelatedInformation